In a small trial with a sample size of 80 subjects Favipiravir had a more potent antiviral action on SARS-CoV-2 than lopinavir/ritonavir.[30] In March 2020, Chinese officials suggested that Favipiravir seemed to be effective in treating COVID-19.[31]
From Japanese instruction leaflet: Favipiravir may have mutagenic effects and thus breast feeding is not allowed and of course also it may not be used for pregnant woman. Man are not allowed to have sex for a certain safety period due to the fact it has been found in seminal fluid.
Favipiravir has been developed to fight the influenza virus but due to the above its no allowed for prime medication in case of influenza unless all other medicaments do fail.
These are mild contraindication compared to the overall large positive effects. Fuji is ramping up production and also China has the right to produce a generic.
This looks like a lucky shot and we all hope that mild to medium progress cases can soon have access to it.
There is a separate therapy - an add-on - for strong infections but my wife could not yet find the details for the add-on.